[{"orgOrder":0,"company":"AIDS Clinical Trials Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sofosbuvir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"AIDS Clinical Trials Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AIDS Clinical Trials Group \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"AIDS Clinical Trials Group \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Velpatasvir

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIDS Clinical Trials Group

                          Country arrow
                          Medlab Asia & Asia Health
                          Not Confirmed

                          AIDS Clinical Trials Group

                          Country arrow
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : ACTG 5360 is a combination of sofosbuvir which is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, whereas velpatasvir is an inhibitor of the HCV NS5A protein, both required for viral replication. Currently being studied for chronic hepatitis C...

                          Brand Name : ACTG 5360

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 23, 2023

                          Lead Product(s) : Sofosbuvir,Velpatasvir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank